Cortec Neuro
The provided search snippets describe the YUME Raptor electric scooter, a personal mobility device featuring high-performance motors, hydraulic suspension, and aerospace aluminum construction.
Classification
Profile
Funding
Funding details not yet available.
Provides a cost-effective, non-invasive BCI system that accelerates motor function recovery in stroke patients through intensive home-based rehabilitation, offering a viable alternative to expensive clinical neurostimulation devices.
B2B2C: Hospitals, rehabilitation centers, and insurance providers targeting stroke survivors requiring motor rehabilitation.
B2B hardware sales and licensing; potential recurring revenue through software updates and clinical outcome services.
Sales-led via clinical partnerships and distributors in the DACH region and expanding internationally.
Collaborations with major German stroke centers and universities for clinical validation; partnerships with regulatory consultants for CE marking.
R&D for EEG hardware and signal processing algorithms; clinical trial costs; regulatory compliance (CE, FDA); manufacturing.
Proprietary EEG hardware design, advanced signal processing algorithms, clinical validation data, founding team with deep neuroengineering expertise.
Hardware and software development, clinical trials, regulatory approval (CE Mark), clinical partnerships, manufacturing.
Sales-led and clinical consultation.
Competes with invasive BCI companies (e.g., Blackrock Neurotech) and non-invasive alternatives like SaeboFlex or traditional therapy. Cortec Neuro differentiates via cost-effectiveness, portability, and focus on intensive home-based stroke rehab.
- Limited availability and high cost of intensive neurorehabilitation therapy. 2. Lack of effective, affordable non-invasive BCI solutions for home use. 3. Delayed recovery times in stroke patients.
- Accelerate EU Regulatory Path - Pursue full CE-Mark for the Brain Interchange™ system to capture the European hospital market, reducing d
- Finalize CE-Mark dossier within 12 months; allocate budget from R&D to regulatory affairs
- Proven Clinical Milestones - First and second human BCI implantations completed within a year, with NIH backing, demonstrate technical fe
No investors recorded yet.